BATTLE-Immunotherapy: a Randomized Phase II trial of trametinib in combination with MK-3475 anti-PD1 antibody versus MK-3475 anti-PD1 antibody in advanced, refractory to frontline chemotherapy NSCLC - Stand Up To Cancer

Blog

Posted October 11, 2019

BATTLE-Immunotherapy: a Randomized Phase II trial of trametinib in combination with MK-3475 anti-PD1 antibody versus MK-3475 anti-PD1 antibody in advanced, refractory to frontline chemotherapy NSCLC

JOIN OUR COMMUNITY

Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.